Istituto Nazionale Malattie Infettive Lazaro Spallanzani Report issue

Academic/Hospital Phase 2 Phase 3

Organization Overview

First Clinical Trial
2017
NCT02972450
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

INMI | IRCCS INMI Lazzaro Spallanzani - Istituto nazionale Malattie Infettive | Istituto Nazionale Malattie Infettive Lazaro Spallanzani | Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani | Istituto Nazionale per le Malattie Infettive "Lazzaro Spallanzani" IRCCS | Istituto per le Malattie Infettive Lazzaro Spallanzani IRCCS | National Institute for the Infectious Diseases (L. Spallanzani) - Rome | Societa' Italiana Di Malattie Infettive E Tropicali

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 3)

Infections (Phase 2)

Pneumonia (Phase 3)

Pneumonia, Viral (Phase 3)

Severe Acute Respiratory Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 10